RxDoctor Payments DataLook up a doctor →

James Strong, MD

Neurology · Birmingham, ALNPI 1619970290

Payments from drug & device makers

$38,661in general payments, 2019–2025

Across 2,182 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • UCB, Inc.$3K
  • Novartis$2K
  • AstraZeneca$2K
  • Biogen$1K
  • Pfizer$1K
  • plus $23K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)426$5,856
UCB, Inc.131$2,560
Novartis121$2,188
AstraZeneca(2 entities)74$1,566
Biogen101$1,363
Pfizer74$1,279
CSL Behring36$1,222
Lilly USA, LLC81$1,199
Neurocrine Biosciences, Inc.60$1,193
Amgen(2 entities)70$1,177
Eisai Inc.50$1,146
Genentech USA, Inc.58$1,086
Acorda Therapeutics, Inc59$1,012
SK Life Science, Inc.45$1,011
EMD Serono, Inc.49$984
Lundbeck LLC45$912
MDD US Operations, LLC16$887
Argenx US, Inc.41$779
Acadia Pharmaceuticals Inc48$774
Teva Pharmaceuticals USA, Inc.47$654
Catalyst Pharmaceuticals, Inc.29$557
Johnson & Johnson(2 entities)37$545
Supernus Pharmaceuticals, Inc.36$533
Upsher-smith Laboratories LLC30$530
Impel Pharmaceuticals Inc.27$508
Sanofi23$507
TG Therapeutics, Inc.19$383
Biohaven Pharmaceuticals, Inc.27$373
Amneal Pharmaceuticals LLC26$357
Tanabe Pharma America, Inc.25$339
Takeda Pharmaceuticals U.S.A., Inc.14$336
Biohaven Pharmaceutical Holding Company Ltd.23$324
Sumitomo Pharma America, Inc.14$287
Greenwich Biosciences, Inc.8$257
Avanir Pharmaceuticals, Inc.13$227
Adamas Pharmaceuticals, Inc.10$215
Merz Pharmaceuticals, LLC9$214
Grifols USA, LLC11$214
Axsome Therapeutics, Inc.13$210
Kyowa Kirin, Inc.11$193
ANI Pharmaceuticals, Inc.8$188
Cycle Pharmaceuticals Inc8$176
Ipsen Biopharmaceuticals, Inc8$176
Bristol Myers Squibb9$168
Neurelis, Inc.11$160
Akcea Therapeutics, Inc.8$150
Aquestive Therapeutics, Inc.9$140
Assertio Therapeutics, Inc.9$137
Sunovion Pharmaceuticals Inc.10$134
Jazz Pharmaceuticals Inc.5$122
Mallinckrodt Hospital Products Inc.5$119
Otsuka America Pharmaceutical, Inc.5$108
Scilex Pharmaceuticals Inc.5$88
Aucta Pharmaceuticals, Inc.5$84
Impel Pharmaceuticals LLC4$74
Boston Scientific4$72
Banner Life Sciences, LLC3$59
Merz North America, Inc.2$55
Avion Pharmaceuticals4$55
Alnylam Pharmaceuticals Inc.2$53

How this compares

$38,661 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$166,074
Medicare patients
302
Services billed
12,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →